Literature DB >> 27018313

B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS.

Matthew W Semler1, Annis M Marney2, Todd W Rice3, Hui Nian4, Chang Yu4, Arthur P Wheeler3, Nancy J Brown5.   

Abstract

BACKGROUND: Conservative fluid management increases ventilator-free days without influencing overall mortality in acute respiratory distress syndrome. Plasma concentrations of B-type natriuretic peptide (a marker of ventricular filling) or aldosterone (a marker of effective circulating volume) may identify patients for whom fluid management impacts survival.
METHODS: This was a retrospective analysis of the Fluid and Catheter Treatment Trial (FACTT), a randomized trial comparing conservative with liberal fluid management in acute respiratory distress syndrome. Using plasma collected at study enrollment, we measured B-type natriuretic peptide and aldosterone by immunoassay. Multivariable analyses examined the interaction between B-type natriuretic peptide or aldosterone concentration and fluid strategy with regard to 60-day in-hospital mortality.
RESULTS: Among 625 patients with adequate plasma, median B-type natriuretic peptide concentration was 825 pg/mL (interquartile range, 144-1,574 pg/mL), and median aldosterone was 2.49 ng/dL (interquartile range, 1.1-4.3 ng/dL). B-type natriuretic peptide did not predict overall mortality, correlate with fluid balance, or modify the effect of conservative vs liberal fluid management on outcomes. In contrast, among patients with lower aldosterone concentrations, conservative fluid management increased ventilator-free days (17.1 ± 9.8 vs 12.5 ± 10.3, P < .001) and decreased mortality (19% vs 30%, P = .03) (P value for interaction = .01).
CONCLUSIONS: In acute respiratory distress syndrome, B-type natriuretic peptide does not modify the effect of fluid management on outcomes. Lower initial aldosterone appears to identify patients for whom conservative fluid management may improve mortality.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute lung injury; aldosterone; brain; natriuretic peptide; water-electrolyte balance

Mesh:

Substances:

Year:  2016        PMID: 27018313      PMCID: PMC4980545          DOI: 10.1016/j.chest.2016.03.017

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  44 in total

1.  Comparison of two fluid-management strategies in acute lung injury.

Authors:  Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin
Journal:  N Engl J Med       Date:  2006-05-21       Impact factor: 91.245

Review 2.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

3.  Aldosterone control in critically ill patients: ACTH, metoclopramide, and atrial natriuretic peptide.

Authors:  H Raff; J W Findling
Journal:  Crit Care Med       Date:  1990-09       Impact factor: 7.598

4.  Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues.

Authors:  A L Gerbes; L Dagnino; T Nguyen; M Nemer
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

5.  Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults.

Authors:  Nor'azim Mohd Yunos; Rinaldo Bellomo; Colin Hegarty; David Story; Lisa Ho; Michael Bailey
Journal:  JAMA       Date:  2012-10-17       Impact factor: 56.272

6.  Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction.

Authors:  Rochus Witthaut; Christian Busch; Peter Fraunberger; Autar Walli; Dietrich Seidel; Günter Pilz; Ralph Stuttmann; Norbert Speichermann; Ljifane Verner; Karl Werdan
Journal:  Intensive Care Med       Date:  2003-08-12       Impact factor: 17.440

7.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

8.  Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock.

Authors:  Roderick H Tung; Christine Garcia; Alexander M Morss; Richard M Pino; Michael A Fifer; B Taylor Thompson; Kent Lewandrowski; Elizabeth Lee-Lewandrowski; James L Januzzi
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

9.  Causes of mortality in patients with the adult respiratory distress syndrome.

Authors:  A B Montgomery; M A Stager; C J Carrico; L D Hudson
Journal:  Am Rev Respir Dis       Date:  1985-09

10.  Association of hypotension with hyperreninemic hypoaldosteronism in the critically ill patient.

Authors:  M W Davenport; R D Zipser
Journal:  Arch Intern Med       Date:  1983-04
View more
  10 in total

1.  Positive Cumulative Fluid Balance Is Associated With Mortality in Pediatric Acute Respiratory Distress Syndrome in the Setting of Acute Kidney Injury.

Authors:  Matt S Zinter; Aaron C Spicer; Kathleen D Liu; Benjamin E Orwoll; Mustafa F Alkhouli; Paul R Brakeman; Carolyn S Calfee; Michael A Matthay; Anil Sapru
Journal:  Pediatr Crit Care Med       Date:  2019-04       Impact factor: 3.624

2.  Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome.

Authors:  Thomas S Metkus; Eliseo Guallar; Lori Sokoll; David A Morrow; Gordon Tomaselli; Roy Brower; Bo Soo Kim; Steven Schulman; Frederick K Korley
Journal:  J Crit Care       Date:  2018-08-16       Impact factor: 3.425

3.  Balanced Crystalloids versus Saline in the Intensive Care Unit. The SALT Randomized Trial.

Authors:  Matthew W Semler; Jonathan P Wanderer; Jesse M Ehrenfeld; Joanna L Stollings; Wesley H Self; Edward D Siew; Li Wang; Daniel W Byrne; Andrew D Shaw; Gordon R Bernard; Todd W Rice
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

4.  Fluid resuscitation targeting sepsis-induced cardiovascular dysfunction: severity of disease as effect modifier.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Differentiating pulmonary transfusion reactions using recipient and transfusion factors.

Authors:  Nareg H Roubinian; Mark R Looney; Sheila Keating; Daryl J Kor; Clifford A Lowell; Ognjen Gajic; Rolf Hubmayr; Michael Gropper; Monique Koenigsberg; Gregory A Wilson; Michael A Matthay; Pearl Toy; Edward L Murphy
Journal:  Transfusion       Date:  2017-05-03       Impact factor: 3.157

Review 6.  Fluid Management in Acute Respiratory Distress Syndrome.

Authors:  Jonathan D Casey; Matthew W Semler; Todd W Rice
Journal:  Semin Respir Crit Care Med       Date:  2019-05-06       Impact factor: 3.119

7.  Fluid management in ARDS: an evaluation of current practice and the association between early diuretic use and hospital mortality.

Authors:  Kevin P Seitz; Ellen S Caldwell; Catherine L Hough
Journal:  J Intensive Care       Date:  2020-10-12

8.  Cardiac biomarkers in acute respiratory distress syndrome: a systematic review and meta-analysis.

Authors:  Dilip Jayasimhan; Simon Foster; Catherina L Chang; Robert J Hancox
Journal:  J Intensive Care       Date:  2021-04-26

Review 9.  Fluids in ARDS: more pros than cons.

Authors:  Renata de S Mendes; Paolo Pelosi; Marcus J Schultz; Patricia R M Rocco; Pedro L Silva
Journal:  Intensive Care Med Exp       Date:  2020-12-18

10.  Centrality of G6PD in COVID-19: The Biochemical Rationale and Clinical Implications.

Authors:  Yuliya Buinitskaya; Roman Gurinovich; Clifford G Wlodaver; Siarhei Kastsiuchenka
Journal:  Front Med (Lausanne)       Date:  2020-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.